Breast Cancer Treatment to get Targeted by the Researchers from the University of Sussex

Release Date: 01-Nov-2020

Researchers have come across a unique set of mechanism of action which is capable of controlling the increasing prevalence rate due to breast cancer. A group of researchers at the University of Sussex have identified a novel target which can be novel treatment regimen for millions of breast cancer patient. As per research conducted by the researchers at the University, Lemur tyrosine kinase 3 (LMTK3) which is linked with endocrine and cell proliferation resistance in case of breast cancer can be effectively turned towards the treatment of breast cancer and some other cancer types.

The novel protein identified by the group of researchers is a protein that has represented itself as an effective oncogenic regulator. The analysis of the crystal structure of the protein LMTK3, it is observed that it consists of all the important hallmarks of a protein kinase activity. As the activity of the protein is specific therefore, the researchers are now keen to introduce the therapy into next stage of research development and develop a drug that specifically follows the respective protein mechanism of action. The next few years of the drug development is estimated to be quite important for the overall cancer therapeutics market.

Some of the high-throughput technologies that uses fluorescence screen have also been used for the biochemical, cellular, and biophysical assay of the small-molecule inhibitor C28, that can effectively inhibit the protein called as LMTK3. As per analysis, it is estimated that the protein which is a major part of the study is also a heat shock protein 90 client protein, which apparently requires the support of HSP90 of proper folding as well as stability, whereas on the other side, C28 leads to the proteasome-mediated degradation of LMTK3.

It has been observed that if the protein called as LMTK3 gets pharmacologically inhibited, it will cause a decrease in the growth of the cancer cells as well as increase of the apoptosis of cancer cells in breast. Also, the inhibition of the protein LMTK3 also leads to the reduced proliferation of transgenic breast cancer mouse models without the development of any side effects. According to the researchers working on the study, it is estimated that their target protein could be

oriented as an effective and potential druggable target in the overall cancer therapeutics market. It is believed that the further opening of the information with respect to protein will lead to the development of the therapy that will be highly beneficial to the cancer patients who haven’t respond to any cancer therapy or have developed resistance to the available cancer therapies.